Cordani David

Cordani sells 201.9K CI shares for $59.1M under pre-arranged 10b5-1 plan; retains 57.8K shares

David Cordani, Chairman & CEO of Cigna Group, executed 13 sales totaling 201,878 shares for $59,114,186.29 on May 12, 2026, pursuant to a pre-arranged 10b5-1 trading plan adopted on 2026-02-06—making this a scheduled, non-discretionary transaction rather than a signal of conviction or concern. While Cordani's prior 19 sell transactions across all tickers achieved an 88.89% well-timed rate at the 90-day mark, the recent stock performance context matters: CI is trading at $294.93, down 13.0% from its 52-week high of $338.89, though up 8.2% over the past 30 days and 1.2% over 90 days. Post-transaction, Cordani retains 57,766 shares, demonstrating continued skin-in-the-game, and Cigna's fundamentals remain solid with $68.5B in annual revenue, $1.7B net income, 11.2% YoY revenue growth, and a 12.41 P/E ratio. The pre-arranged plan status limits the signaling power of this sale for inferring current insider sentiment.

Cigna CEO Cordani buys 4,134 shares for $999.9K; stock down 24.6% from 52-week high, holdings rise 2.7%

David Cordani, Chair & CEO of Cigna Group, purchased 4,134 shares at $241.88 on 2025-11-03 for a total value of $999,916.21, increasing his holdings from 153,801 to 157,935 shares (+2.7%). The purchase occurred while the stock trades at $258.62, down 24.6% from its 52-week high of $343.06 and down 16.8% over the past 30 days. Cordani's prior sell activity at this ticker shows strong timing discipline: 4 of 5 prior CI sales resulted in negative 90-day returns, indicating he consistently sold before declines. His cross-ticker track record reflects a 88.89% well-timed sell rate, suggesting consistent pattern recognition in market conditions. Against this backdrop, this open-market purchase during a significant drawdown warrants investor attention as a signal from a history-proven trader, though it should be evaluated alongside the company's fundamentals: Cigna reported $69.7B in latest-quarter revenue, $2.0B net income, 26.6% annual revenue growth, and a P/E of 10.55, indicating a mature, profitable business trading at reasonable valuation.

Cordani sold 26,527 CI shares at $308.12 for $8.2M; down -17.2% from prior holdings. 5 of 5 prior CI sales were well-timed.

David Cordani, Chairman & CEO, sold 26,527 shares of Cigna Group on 2025-03-03 at $308.12, reducing his holdings to 127,767 shares. His entire 5-trade history at this ticker shows well-timed sales: each prior CI sale resulted in negative 90-day returns ranging from -2.2% to -5.7%, indicating the stock declined after each sale. His cross-ticker track record reinforces this pattern with a 94.12% well-timed rate across 20 prior sells averaging -3.0% 90-day return. The current price of $308.86 is -15.8% from the 52-week high of $366.85, and Cigna trades at a P/E of 48.18 on $63.7B in quarterly revenue and positive 26.6% annual revenue growth. The sale is modest in absolute terms ($8.2M) against a $84.5B market cap, yet the consistent pattern of well-timed selling at this ticker warrants monitoring for any signal about insider conviction at current valuations.